Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NT5C1B-RDH14 readthrough is a naturally occurring chimeric transcript and protein resulting from read-through transcription between the NT5C1B (5′-nucleotidase, cytosolic IB) gene and RDH14 (retinol dehydrogenase 14) gene on chromosome 2. The readthrough encodes a fusion protein that contains sequence from both parent genes; the main known functional domains are nucleotide binding and potential magnesium ion binding, derived from the NT5C1B component. This fusion has no established role as a therapeutic target, receptor, or druggable protein, and there is no evidence of specific disease involvement or biomarker utility for this readthrough product. The functional significance is poorly defined, and most research attributes biological and disease relevance to the individual parent genes rather than the read-through product itself[2][6][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NT5C1B-RDH14 readthrough (NT5C1B-RDH14).